Evidence map›Paper›PMID 35003132›Full record

ArticleFrontiers in immunology2021

S-540956, a CpG Oligonucleotide Annealed to a Complementary Strand With an Amphiphilic Chain Unit, Acts as a Potent Cancer Vaccine Adjuvant by Targeting Draining Lymph Nodes.

Takayuki Nakagawa, Tetsuya Tanino, Motoyasu Onishi, Soichi Tofukuji, Takayuki Kanazawa, Yukichi Ishioka, Takeshi Itoh, Akira Kugimiya, Kazufumi Katayama, Takuya Yamamoto and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Designing nucleic acid-based therapeutics for cancer treatment: Updates on the state of the art.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Takayuki NakagawaPharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan.
Tetsuya TaninoPharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan.
Motoyasu OnishiPharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan.
Soichi TofukujiPharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan.
Takayuki KanazawaPharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan.
Yukichi IshiokaPharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan.
Takeshi ItohPharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan.
Akira KugimiyaPharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan.
Kazufumi KatayamaPharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan.
Takuya YamamotoLaboratory of Adjuvant Innovation, Center for Vaccine and Adjuvant Research (CVAR), National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.
Morio NagiraPharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan.
Ken J IshiiLaboratory of Adjuvant Innovation, Center for Vaccine and Adjuvant Research (CVAR), National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.
Shionogi (Japan) · JPNational Institute of Biomedical Innovation, Health and Nutrition · JPThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Robust induction of cancer-antigen-specific CD8

Indexed as

Adjuvants, VaccineAnimalsCancer VaccinesCD8-Positive T-LymphocytesCell DifferentiationDendritic CellsDNAFemaleHumansImmunizationLung NeoplasmsLymphocyte ActivationMiceMice, Inbred C57BLNeoplasms, ExperimentalOligodeoxyribonucleotidesAdjuvants, VaccineCancer VaccinesCPG-oligonucleotideDNAODN2006Oligodeoxyribonucleotidesoncogene protein E7, Human papillomavirus type 16Papillomavirus E7 ProteinsSurface-Active AgentsToll-Like Receptor 9Vaccines, Subunitadjuvantcancer peptide vaccineCpG oligonucleotidedelivery systemdraining lymph node

Identifiers

PMID35003132
PMCPMC8735836
OpenAlexW4200039881

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.